KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for Astrazeneca (AZN) over the last 17 years, with Q4 2025 value amounting to $7.9 billion.

  • Astrazeneca's Cash & Current Investments rose 1143.26% to $7.9 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $7.9 billion, marking a year-over-year increase of 1143.26%. This contributed to the annual value of $7.9 billion for FY2025, which is 1143.26% up from last year.
  • As of Q4 2025, Astrazeneca's Cash & Current Investments stood at $7.9 billion, which was up 1143.26% from $10.1 billion recorded in Q3 2025.
  • Astrazeneca's 5-year Cash & Current Investments high stood at $16.6 billion for Q2 2021, and its period low was $5.5 billion during Q3 2022.
  • Moreover, its 5-year median value for Cash & Current Investments was $7.0 billion (2022), whereas its average is $7.8 billion.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first skyrocketed by 21822.27% in 2021, then crashed by 6429.47% in 2022.
  • Over the past 5 years, Astrazeneca's Cash & Current Investments (Quarter) stood at $6.4 billion in 2021, then decreased by 0.11% to $6.4 billion in 2022, then fell by 6.92% to $6.0 billion in 2023, then rose by 19.42% to $7.1 billion in 2024, then rose by 11.43% to $7.9 billion in 2025.
  • Its Cash & Current Investments stands at $7.9 billion for Q4 2025, versus $10.1 billion for Q3 2025 and $8.9 billion for Q2 2025.